The short answer to “what happens if I stop” is that nobody has measured it in adults. In children, growth rates returned to their pretreatment level after stopping. A single missed dose most plausibly means one missed growth hormone pulse, but that is an inference from how the drug works, not a tested finding.
What happens if you miss a dose of sermorelin?
No published trial has measured what happens after one skipped dose. A PubMed search for sermorelin combined with the terms missed dose or dose omission returns zero results. A parallel search for sermorelin and discontinuation returns two records, both from the 1990s. Both mention that treatment was stopped early for a handful of patients who were not responding well. Neither is a study of what happens after stopping. That gap is worth stating first, because a missed dose is the most common real question, and the literature simply does not answer it directly.
What can be said comes from the drug’s mechanism, not a dedicated study. In the best-documented adult trial, a single nightly injection produced a growth hormone pulse within ten minutes, lasting roughly two hours [1]. That is the same nightly regimen covered in the dosage breakdown. See what that trial measured for the full outcome picture. That short pulse describes a short-acting stimulus, not a drug that builds up or needs an unbroken chain of doses to keep working. By that mechanistic logic, a missed night most plausibly means missing that night’s pulse, not triggering a rebound or withdrawal effect. That is a reasonable inference, not a tested finding, and it should be labeled that way.
What happens when you stop sermorelin?
Here the literature does say something, and it comes from exactly one trial, in a population that is not who buys sermorelin today.
A small pediatric trial gave eight children with slow growth a continuous subcutaneous GHRH infusion for up to a year. It then tracked what happened after treatment stopped. The finding was direct: growth rates returned to pretreatment levels in every child who stopped [2]. Growth velocity had risen from roughly 4.6 to 7.0 cm per year during the year of treatment in the children who completed it. After stopping, growth slowed back toward where it started.
A second pediatric trial tracked a different measure after stopping: antibodies against GHRH itself. Ninety-five to one hundred percent of treated children developed measurable anti-GHRH antibodies during treatment, a striking rate. Those antibodies had almost disappeared by nine months after stopping, with no link found between antibody level and how much a child had actually grown [3]. The immune response the drug provoked faded once treatment ended, the same as the growth effect.
Does the pediatric data apply to adults?
Read those two findings for what they are: a reversion toward baseline in a growth measurement, and a fading antibody response. Both come from children. Both come from a dosing schedule that does not match what is commonly sold to adults today. They are the only sermorelin-family discontinuation findings in the published literature.
No adult discontinuation study exists. The best-documented adult trial ran active treatment for roughly sixteen weeks and reported no follow-up after it ended [1]. Nobody measured what happened to those adults’ lean mass or well-being once they stopped. The before-and-after read of that same trial covers this gap directly. It is not a footnote. It is the entire state of adult discontinuation evidence: absent.
The mechanistic expectation is straightforward. GH and IGF-1 should drift back toward an individual’s own baseline once nightly stimulation stops, because sermorelin does not permanently change how the pituitary works. That lines up with what the pediatric growth data actually showed. But it is an inference, not a measured adult finding, and treating it as settled would overstate what anyone has shown.
How long can you take sermorelin?
No study has set a maximum. The longest adult evidence is the one placebo-controlled trial, which ran active treatment for about sixteen weeks [1]; nothing is published on adults taking it for a year or longer, so sixteen weeks is the ceiling of what has been measured, not a limit anyone tested. In children, continuous dosing ran for a year and the pituitary kept responding [2].
That is also why there is no evidence-based “cycle.” Sellers commonly describe three- to six-month courses, or five nights on and two off, but no trial compared one schedule against another or tested whether breaks preserve the effect. How long to stay on, and whether to pause, is a decision to make with the prescriber who is monitoring you, ideally with an IGF-1 level checked along the way.
Why is there so little research on stopping?
It helps to understand why adult discontinuation data is missing, not just that it is. Every randomized controlled sermorelin trial ever indexed in PubMed, in any population, for any purpose, numbers exactly ten. Trials are expensive and slow. They get designed around the question that funded them, mostly pediatric growth outcomes decades ago, not an adult’s lean mass months after stopping. A follow-up phase asking what happens after treatment ends adds cost and time. It adds that cost to a trial that already runs for months just to show an effect. With only ten trials in the drug’s history, the odds that one happened to include an adult discontinuation arm were never high. That is not an excuse for the gap. It is the reason it exists.
What should you do if you miss doses or want to stop?
The honest state of the evidence is reasonable inference, not measurement. So if you are missing doses or thinking about stopping, the practical move is not to guess your way through it. It is the same move as any other prescription change: talk to whoever is prescribing or monitoring your treatment. Pair that conversation with a look at what has and hasn’t been reported as a side effect. They can account for your specific situation in a way a general, mechanism-based inference cannot.
The bottom line
A missed single dose is, by mechanism, most plausibly just a missed pulse — not tested directly, but consistent with how fast and short-acting the drug’s one documented action is [1]. Full discontinuation has been measured exactly once, in eight children, on growth velocity, with a clean reversion to baseline [2]. Antibody levels induced during treatment also faded after stopping, in a separate pediatric trial [3]. Nobody has measured what happens when an adult stops. That is the honest gap, stated once, plainly, instead of filled in with something that sounds more complete than it is.